Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.84 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.60 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | LSS | P48449 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151597 | 0.92 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6151453 | 0.88 | SLC6A4 (0.84) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6152112 | 0.88 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6151331 | 0.86 | SLC6A4 (0.85) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL5878554 | 0.78 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3SCN9ALSS | |
| SCHEMBL6153185 | 0.77 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6151917 | 0.75 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL22721342 | 0.74 | PARP10 (0.70) | SLC6A4SLC6A2SCN9APARP10 | |
| SCHEMBL6151207 | 0.73 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL6152245 | 0.73 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268396-B1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2005-07-20 | — | — | EP | disclosed |
| US-6448293-B1 | TREATMENT OR PREVENTION OF A DISORDER IN WHICH THE REGULATION OF MONOAMINE TRANSPORTER FUNCTION IS IMPLICATED, SUCH AS PREMATURE EJACULATION. | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | ANDREWS MARK DAVID (GB) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | CBR1, OGFR, CBR3 | SLC6A4 2002/4885SLC6A2 1349/4885SLC6A3 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.